BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Leqembi (Lecanemab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Leqembi (Lecanemab)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06602258-665@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Leqembi (Lecanemab): Phase 2 readout est. (NCT06602258)
DESCRIPTION:Leqembi (Lecanemab)\, phase 2\, Alzheimer's Disease.\nStudy: A 
 Study of E2814 With Concurrent Lecanemab Treatment in Participants With Ea
 rly Alzheimer's Disease\nEstimated primary completion: 3 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06602258
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03887455-665@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT03887455)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study to Confirm Safety and Efficacy of Lecanemab in Participants With Ear
 ly Alzheimer's Disease\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03887455
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604896-665@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Leqembi (Lecanemab): Phase 4 readout est. (NCT07604896)
DESCRIPTION:Leqembi (Lecanemab)\, phase 4\, Alzheimer's Disease.\nStudy: Ev
 aluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Throu
 gh Multi-omics Approachs\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07604896
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01760005-665@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Leqembi (Lecanemab): Phase 2/3 readout est. (NCT01760005)
DESCRIPTION:Leqembi (Lecanemab)\, phase 2/3\, Alzheimer's Disease.\nStudy: 
 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent De
 mentia. A Study of Potential Disease Modifying Treatments in Individuals a
 t Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a G
 enetic Mutation. Master Protocol DIAN-TU-001\nEstimated primary completion
 : April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lecanem
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 1760005
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07212062-665@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Leqembi (Lecanemab): Phase 2 readout est. (NCT07212062)
DESCRIPTION:Leqembi (Lecanemab)\, phase 2\, Alzheimer's Disease.\nStudy: Th
 e Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+
 X-EC in Participants With Alzheimer's Disease Who Are Currently Treated Wi
 th Lecanemab.\nEstimated primary completion: 1 April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lecanemab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07212062
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04468659-665@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT04468659)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: AH
 EAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With 
 Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevate
 d Amyloid and Also in Participants With Early Preclinical Alzheimer's Dise
 ase and Intermediate Amyloid\nEstimated primary completion: 21 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04468659
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07688460-665@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Leqembi (Lecanemab): Phase 4 readout est. (NCT07688460)
DESCRIPTION:Leqembi (Lecanemab)\, phase 4\, Alzheimer's Disease.\nStudy: Ev
 aluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor
  Alzheimer's Biomarkers\nEstimated primary completion: 30 March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07688460
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05469009-665@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Leqembi (Lecanemab): Phase 1 readout est. (NCT05469009)
DESCRIPTION:Leqembi (Lecanemab)\, phase 1\, Alzheimer's Disease.\nStudy: Sa
 fety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild C
 ognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Car
 e Monoclonal Antibody (mAb) Therapy\nEstimated primary completion: July 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/lecanemab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05469009
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06384573-665@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Leqembi (Lecanemab): Phase 3 readout est. (NCT06384573)
DESCRIPTION:Leqembi (Lecanemab)\, phase 3\, Alzheimer's Disease.\nStudy: DI
 AN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Dise
 ase\nEstimated primary completion: June 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/lecanemab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06384573
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07544953-665@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Leqembi (Lecanemab): Phase na readout est. (NCT07544953)
DESCRIPTION:Leqembi (Lecanemab)\, phase na.\nStudy: Amyloid Monoclonal Anti
 body Treatment in PD Patients With Coexistent AD Pathology\nEstimated prim
 ary completion: June 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lecanemab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07544953
URL:https://assetmemo.bio/drug/lecanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
